AstraZeneca to list directly on NYSE while keeping U.K. listing; shares up
PositiveFinancial Markets

AstraZeneca has announced its decision to list directly on the New York Stock Exchange while maintaining its existing listing in the U.K. This move is significant as it reflects the company's growth and ambition in the global market, and the positive response is evident with shares rising. Investors are likely to view this dual listing as a strong indicator of AstraZeneca's commitment to expanding its presence in the U.S., which could lead to increased investor confidence and further financial opportunities.
— Curated by the World Pulse Now AI Editorial System